Activity of propyl-propane-thiosulfinate and propyl-propane-thiosulfonate against carbapenem-resistant Gram-negative bacteria
- PMID: 38757239
- DOI: 10.1111/apm.13420
Activity of propyl-propane-thiosulfinate and propyl-propane-thiosulfonate against carbapenem-resistant Gram-negative bacteria
Abstract
Organosulfur compounds derived from plants of the Allium genus, such as propyl-propane-thiosulfinate (PTS) and propyl-propane-thiosulfonate (PTSO), have been proposed as an alternative in antibiotic resistance. The aim of this study was to compare the activity of these substances with other antibiotics against clinical isolates of carbapenem-resistant (CAR-R) and carbapenem-susceptible (CAR-S) Gram-negative bacteria. A total of 126 clinical isolates of CAR-R and 155 CAR-S bacteria were selected, including Enterobacterales, A. baumannii and P. aeruginosa. The antibiotic susceptibility of all isolates was assessed using the microdilution and Kirby-Bauer methods for PTS, PTSO, amoxicillin/clavulanate, piperacillin/tazobactam, cefotaxime, ceftazidime, cefepime, imipenem, ciprofloxacin, and amikacin. Both PTS and PTSO demonstrated in vitro bactericidal activity against CAR-R Enterobacteriaceae and A. baumannii, with no significant difference in activity compared to their response against CAR-S isolates. However, both compounds were less active against P. aeruginosa than against any of the other bacteria, regardless of their resistance to carbapenems. In all cases, the minimum inhibitory concentration values of PTSO were significantly lower than those of PTS. These findings offer valuable information about the potential antibacterial use of these substances, particularly against infections that currently have limited therapeutic options.
Keywords: Gram‐negative bacilli; antibacterial activity; carbapenemases; propyl‐propane‐thiosulfinate; propyl‐propane‐thiosulfonate.
© 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
References
REFERENCES
-
- Mousavi SM, Babakhani S, Moradi L, Karami S, Shahbandeh M, Mirshekar M, et al. Bacteriophage as a novel therapeutic weapon for killing colistin‐resistant multi‐drug‐resistant and extensively drug‐resistant gram‐negative bacteria. Curr Microbiol. 2021;78:4023–4036.
-
- Meng H, Han L, Niu M, Xu L, Xu M, An Q, et al. Risk factors for mortality and outcomes in hematological malignancy patients with carbapenem‐resistant Klebsiella pneumoniae bloodstream infections. Infect Drug Resist. 2022;15:4241–4251.
-
- Montrucchio G, Costamagna A, Pierani T, Petitti A, Sales G, Pivetta E, et al. Bloodstream infections caused by carbapenem‐resistant pathogens in intensive care units: risk factors analysis and proposal of a prognostic score. Pathogens. 2022;11:718.
-
- Sánchez‐García JM, Sorlózano‐Puerto A, Navarro‐Marí JM, Gutiérrez Fernández J. Evolution of the antibiotic‐resistance of microorganisms causing urinary tract infections: a 4‐year epidemiological surveillance study in a hospital population. Rev Clin Esp (Barc). 2019;219:116–123.
-
- Garnacho‐Montero J, Amaya‐Villar R. The problem of multi‐resistance in gram‐negative bacilli in intensive care units: treatment and prevention strategies. Med Intensiva. 2022;46:326–335.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
